+39 02 610346.1 - info@newron.com

2007

Fact sheet

20/12/2007

Safinamide 18-Month Phase III results conference call MP 3 file

22/08/2007

Ralfinamide Positive Phase II results - Press confererence MP3 file

02/07/2007

Safinamide - Abstracts from Movement Disorder Society's 11th International Congress, Istanbul

07/06/2007

Safinamide, a New Anti-Parkinson Agent, is Effective and well-tolerated in Early Parkinson’s Disease PD Patients on a Stable Dose of a Single DA-Agonist: Results of a Randomized, International, Placebo-controlled, Phase III Trial.

10/05/2007

Full-Year Results 2006 - Press Conference MP3 File

29/03/2007